FDA on November 10 granted marketing approval to the New York Blood Center’s allogeneic cord-blood product, Hemacord, the first U.S.-licensed hematopoietic progenitor cell therapy.
Hemacord is indicated for hematopoietic progenitor cell transplantation procedures in patients with inherited,